Pharmsynthez
Pharmsynthez is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Pharmsynthez.
Pharmsynthez is a company.
Key people at Pharmsynthez.
Pharmasyntez is one of Russia's leading biopharmaceutical companies, specializing in the development, production, and supply of socially important medicines, particularly antitubercular, antineoplastic, antiretroviral drugs, hospital antibiotics, and treatments for HIV/AIDS, oncology, and other critical diseases.[1][2][6] The company serves patients, healthcare institutions, and partners across Russia and exports to CIS countries like Kazakhstan, Uzbekistan, and Belarus, addressing shortages in accessible, high-quality drugs through import substitution and generics while investing in innovative originals.[1][2][3] With over 300 drug products, 60+ active pharmaceutical substances, and production in diverse forms like tablets, injectables, and infusions across five GMP-compliant factories, Pharmasyntez employs more than 5,000 specialists and demonstrates strong growth, ranking in Russia's top pharmaceutical producers since 2011.[1][2][4][5]
Pharmasyntez was founded in 1997 in Irkutsk, Russia, starting with a focus on antitubercular generics amid rising TB challenges.[2][3][5] The first factory opened in 1999, rapidly expanding its TB drug lineup to over 50 products and pioneering Perchlozone®, a novel antitubercular medicine for multi-drug resistant strains, now used in 120 countries after clinical success and inclusion in Russia's vital drugs list (VED).[1][3] Key milestones include new factories in Ussuriysk, Tyumen (2015 for infusions and hormonals), Bratsk (2014 for high-tech substances), and St. Petersburg; by 2017, it held top-3 growth status, producing 50% of Russia's antitubercular and 45% of antiretroviral drugs with a 115-product portfolio.[3][4] This evolution reflects a shift from generics to innovation, backed by annual R&D investments up to 500 million rubles.[2]
Pharmasyntez rides the wave of pharmaceutical sovereignty in Russia, capitalizing on import substitution trends post-sanctions to boost domestic production of critical drugs amid global supply disruptions.[1][2] Timing aligns with rising needs for TB, HIV, and oncology treatments in BRICS nations and CIS markets, where it fills gaps in affordable, effective therapies—producing over half of Russia's TB drugs.[3][6] Market forces like government support (e.g., Irkutsk investment approvals) and R&D incentives favor its expansion, while collaborations enhance tech transfer and exports.[1][3] It influences the ecosystem by elevating Russia's biopharma capabilities, reducing reliance on Western imports, and exporting innovations like Perchlozone® to 120 countries, fostering regional self-sufficiency.[1][3][7]
Pharmasyntez is poised for continued expansion through new drug launches (e.g., more oncology, hepatitis, diabetes), factory scaling, and international partnerships, targeting US/EU markets with originals as announced in 2016.[3][7] Trends like BRICS cooperation (e.g., 2025 India-Russia commission) and sustained R&D will drive growth, potentially increasing its global footprint amid ongoing import substitution demands.[1][6] Its influence may evolve from domestic leader to key exporter, solidifying Russia's biopharma role—building on its foundation as a lifesaving drug innovator accessible to those who need it most.[2][6]
Key people at Pharmsynthez.
